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Abstract
Background:  The mechanisms responsible for the maintenance of pluripotency in human
embryonic stem cells, and those that drive their commitment into particular differentiation
lineages, are poorly understood. In fact, even our knowledge of the phenotype of hESC is limited,
because the immunological and molecular criteria presently used to define this phenotype describe
the properties of a heterogeneous population of cells.
Results:  We used a novel approach combining immunological and transcriptional analysis
(immunotranscriptional profiling) to compare gene expression in hESC populations at very early
stages of differentiation. Immunotranscriptional profiling enabled us to identify novel markers of
stem cells and their differentiate d  p r o g e n y ,  a s  w e l l  a s  n o v e l potential regulators of hESC
commitment and differentiation. The data show clearly that genes associated with the pluripotent
state are downregulated in a coordinated fashion, and that they are co-expressed with lineage
specific transcription factors in a continuum during the early stages of stem cell differentiation.
Conclusion: These findings, that show that maintenance of pluripotency and lineage commitment
are dynamic, interactive processes in hESC cultures, have important practical implications for
propagation and directed differentiation of these cells, and for the interpretation of mechanistic
studies of hESC renewal and commitment. Since embryonic stem cells at defined stages of
commitment can be isolated in large numbers by immunological means, they provide a powerful
model for studying molecular genetics of stem cell commitment in the embryo.
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Background
The first seven years of research on human embryonic
stem cells (hESC) have led to significant advances in our
ability to maintain and manipulate these fascinating cul-
tured cell lines [1-3]. The initial reports of the derivation
of pluripotent stem cells from the human blastocyst [4,5]
have been abundantly confirmed, technology for the
maintenance and manipulation of hESC has been success-
fully disseminated around the world, and there have been
improvements to the culture system used in the first deri-
vations. The differentiation in vitro of hESC into a variety
of tissue types of enormous potential significance to
research and medicine, including neural tissue, blood,
cardiac muscle, and many others, has been reported, and
the first studies showing proof of principle of the applica-
tion of hESC-derived neural cells in preclinical animal
models of disease have recently been published [6,7].
While this record is impressive, very significant challenges
remain ahead if hESC are actually going to fulfill their
potential. The reality is that even our basic understanding
of the phenotype of human pluripotent stem cells is lim-
ited. hESC are characterized by their immunological pro-
file, by transcriptional analysis, and by biological assay of
their capability for self-renewal and multilineage differen-
tiation. Most work carried out on hESC has made the tacit
assumption that the canonical hESC phenotype-a cell
positive for specific surface antigens (SSEA-3, SSEA-4,
TRA-1–60, CD9), expressing genes specific to pluripotent
cells (e.g., Oct-4, nanog), and capable of indefinite
renewal and differentiation into derivatives of all three
embryonic germ layers-essentially describes a single dis-
crete cellular entity. However, the canonical description of
the phenotype of the hESC in fact describes the properties
of a heterogeneous population of cells, some of which
have embarked on the pathway to differentiation. Because
of this, and because the early stages of hESC commitment
and differentiation are largely uncharted, present studies
at the cellular, molecular and biochemical level, which
treat hESC cultures as a homogeneous population of cells,
are capable of providing only limited insight into the con-
trol of stem cell renewal and differentiation. In particular,
the numerous studies of the hESC transcriptome and pro-
teome, [8-19] which generally have compared hESC pop-
ulations grown under conditions that support renewal to
cultures undergoing overt differentiation, have produced
a molecular blueprint of the pluripotent state, but this
blueprint is limited in its resolution due to the inherent
complexity of the cell populations under comparison.
The structure of stem cell differentiation hierarchies in
general, and that of hESC in particular, is often depicted
as a series of binary choices between alternate and discrete
cell states, driven by a serial cascade of expression of spe-
cific transcription factors. However, other data indicate
that for pluripotent stem cells at least, the early progres-
sion through a differentiation hierarchy is in fact a contin-
uum that may be reversibly traversed [20]. In fact,
emerging concepts regarding cell fate choice in the preim-
plantation mouse embryo support a less rigid interpreta-
tion of the process of lineage commitment. A newer
model [21] depicts the formation of three specific lineages
of the mammalian periimplantation embryo, inner cell
mass, trophectoderm, and extraembryonic endoderm, not
as a sequence of binary decisions, but as the result of a
dynamic interplay of expression of a network of particular
regulatory genes. Specifically, networks of key transcrip-
tional regulators, including Oct-4, nanog, cdx-2 and
GATA -4 and -6, interact in a spatially restricted fashion in
the preimplantation embryo to determine fate, rather
than acting in a sequential mode, as recently illustrated for
commitment to the trophectoderm lineage [22,23]. These
findings imply that in early development, the process of
lineage choice begins early, before overt loss of all stem
cell maintenance factors, and occurs through a set of
opposing reciprocal interactions between key transcrip-
tion factors. These concepts are reminiscent of the model
of lineage priming, derived from studies of hematopoie-
sis, in which expression of genes characteristic of multiple
differentiation lineages is observed in stem or progenitor
cells that have not yet undertaken overt commitment [24-
26]. A recent study [27] of the transcriptional regulatory
circuits in hESC predicts that cell fate is the result of a
dynamic interplay between key regulatory factors, and
that alterations in stoichiometry between these factors
lead to global changes in gene expression and ultimately
cell commitment to specific lineages. Furthermore, this
study highlighted a key role for pluripotency genes in the
suppression of the expression of many lineage specific
transcription factors.
In this study we sought to analyse the early stages in hESC
differentiation through an approach we call immunotran-
scriptional profiling. We used flow cytometry to fraction-
ate hESC populations grown under conditions that
support stem cell renewal on the basis of their levels of
expression of two surface markers. Following fractiona-
tion, each population was subjected to transcriptome
analysis via microarray. Critical findings were confirmed
by low density array quantitative reverse transcriptase
polymerase chain reaction (QRT-PCR). The results iden-
tify new markers of the pluripotent state and potential
paracrine regulators of cell fate, and they provide evidence
for a continuum of expression of pluripotency genes and
lineage specific transcription factors across the popula-
tion.BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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Results
Antibodies to epitopes expressed on the surface of primate 
pluripotent stem cells reveal heterogeneity in hESC 
cultures
In our investigations we used three monoclonal antibod-
ies recognising canonical markers of hESC. The first was
the monoclonal antibody GCTM-2, which recognises an
epitope on the protein core of a high molecular weight
pericellular matrix keratan sulphate/chondroitin sulphate
proteoglycan [28]. A recent study identified the GCTM-2
antigen as the CD34 related sialomucin podocalyxin [29].
To assess this conclusion, which was based primarily on
copurification of the GCTM-2 antigen and podocalyxin
on lectin affinity columns, we transfected a mouse kidney
cell line with human podocalyxin cDNA. Anti-podoca-
lyxin antibodies detected a band of the appropriate
molecular weight in immunoblots of extracts, but there
was no reaction with either GCTM-2, TG343 (another
antibody reactive with a distinct epitope on the core pro-
tein of the proteoglycan, [30]) or the antibody TRA-1–60,
which reacts with a carbohydrate epitope on the same
molecule (Figure 1a). While both GCTM-2 and anti-podo-
calyxin antibodies stained cells in hESC cultures, the pop-
ulations stained were distinct (Figure 1b), and in the
human kidney, GCTM-2 stained tubular epithelium
weakly whilst anti-podocalyxin antibodies stained podo-
cytes as expected (Figure 1c–d). Thus it is not clear that the
GCTM-2 antigen and podocalyxin represent the same
molecular entity; it is however apparent that podocalyxin
antibodies recognise cells that GCTM-2 does not.
We also used monoclonal antibody TG30, produced by
immunisation of mice with a partially purified prepara-
tion of the GCTM-2 antigen. TG30 reacts with a cell sur-
face epitope on a 25 kDa protein. This epitope was
identified as the tetraspannin protein CD9 following
transfection of mouse STO cells with a human CD9 cDNA
clone and demonstration of reactivity of the transfected
cells with TG30 (Figure 1e). Others have reported expres-
sion of CD9 in hESC [14]. Finally we used a monoclonal
antibody against the transcription factor Oct3/4, a mole-
cule with long established function in the maintenance of
pluripotency in mouse ES cells [31]; recent data strongly
supports a similar role for this transcription factor in hESC
[32,33].
HESC grown in serum-containing medium in the pres-
ence of mouse embryonic fibroblast feeder cell support
were examined by double and triple label indirect
immunofluorescence (Figure 2). The cultures were heter-
ogeneous in their expression of these surface markers. In
healthy growing colonies prior to overt cellular differenti-
ation, only those cells at the edge of the colony expressed
all three markers. Further in towards the colony centre,
GCTM-2 staining was reduced, but CD9 and Oct-4 stain-
ing remained high. As differentiation proceeded, the inte-
rior of the colony became negative for all of these markers
but the outer rim remained positive.
Reactivity of the hybridomas GCTM-2 and TG30 used to  fractionate hESC by flow cytometry Figure 1
Reactivity of the hybridomas GCTM-2 and TG30 used to 
fractionate hESC by flow cytometry. A, Protein lysate from 
M15 cells transfected (T) with the full-length human podoca-
lyxin construct, pcDNA3/Podxl, shows immunoreactivity to 
podocalyxin antibodies (PHM5). In contrast, no immunoreac-
tivity was observed with GCTM-2, TG343 or TRA 1–60 anti-
bodies, nor in the untransfected (UT) cells. B, Indirect 
immunofluorescent staining of hESC for podocalyxin (green) 
and GCTM-2 (red). C, Human kidney stained for GCTM-2. 
D, Human kidney stained for podocalyxin. E, Mouse STO 
cells transfected with human CD9 cDNA stained by indirect 
immunofluorescence for CD9 (red) and TG30 (green) and 
DAPI (blue). CD9 and TG30 staining is entirely coincident. 
Bar in B-E = 100 μm.BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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Levels of expression of stem cell surface antigens GCTM-2 
and CD9 correlate with levels of Oct-4 expression
The results above were suggestive of a gradient of antigen
expression in growing colonies of hESC, but these indirect
immunofluorescence data were qualitative only. The het-
erogeneity of antibody staining apparent on indirect
immunofluorescence prompted us to carry out quantita-
tive analysis of antigen expression by flow cytometry. We
sought to establish the relationship between staining lev-
els for the two surface antigens and intracellular levels of
Oct-4 protein. Flow cytometric analysis of healthy grow-
ing colonies of hESC prior to overt differentiation showed
that there was a gradient in staining levels for the surface
antigens; most cells expressed both antigens, but some
expressed only one or the other (Figure 3, top panel).
There was a strong relationship between the levels of
expression of Oct-4 and the intensity of double surface
staining for GCTM-2 and CD9 (Figure 3, lower panel).
Thus, the cell population expressing the highest level of
both surface markers also expressed the highest level of
Oct-4 positivity.
Microarray analysis of gene expression in immunologically 
defined subpopulations of hESC shows coordinated 
regulation of gene expression and surface markers
The relationship between levels of expression of two stem
cell markers and the transcription factor Oct-4 suggested
the possibility that there might be an overall gradient of
expression of stem cell markers in the hESC populations.
To assess this we used microarray analysis to examine glo-
bal gene expression patterns in immunologically defined
subpopulations of hESC. Cells were sorted into four sepa-
rate populations (Figure 4a), according to their expression
of both surface markers, RNA was isolated, cDNA pre-
pared, subjected to linear amplification, and then ana-
lysed by Compugen microarray.
We carried out global analysis of those genes showing sig-
nificantly different levels of expression in P7 (GCTM-
2HIGHCD9HIGH) versus P4 (GCTM-2-CD9-), P5 (GCTM-
2LOWCD9LOW) and P6 (GCTM-2MIDCD9MID). A two-fold
difference in expression levels and a B-statistic greater
than zero were the criteria used to identify significant
changes. The detection rates were: P7 versus P6, 12,497/
19,317 genes present; P7 versus P5, 12,094/19,317 genes
present; and P7 versus P4, 15,059/19,317 present.
Most genes whose expression levels changed significantly
showed consistent increases or decreases across the overall
population, and only a small minority fluctuated up and
down (Figure 4b). In all, the total number of significant
changes in gene expression comparing P7 with the other
populations were: P7 versus P6, 293 genes, with 264
higher in P7; P7 versus P5, 392 genes, 271 with higher in
Triple label indirect immunofluorescence examination of stem cell marker expression in growing colonies of hESC Figure 2
Triple label indirect immunofluorescence examination of stem cell marker expression in growing colonies of hESC. A&D 
GCTM-2 (blue) and Oct-4 (red). B&E GCTM-2 (blue) and CD9 (green). C&F CD9 (green) and Oct-4 (red). Scale bar = 200 
μM.BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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P7; P7 versus P4, 1051 genes, with 672 higher in P7.
Inspection of the entire dataset (GEO Accession Number
GSE4020) shows that changes in the expression of genes
associated with the pluripotent state and those associated
with early commitment events occur dynamically before
the extinction of surface marker expression.
The comparison of the two most closely related subpopu-
lations of cells, P7 and P6 [see Additional File 1, array data
for all genes changing significantly between the two pop-
ulations; and Table 1, data for selected genes from all four
populations], both of which expressed relatively high lev-
els of CD9 and GCTM-2 antigen, was highly informative.
This comparison showed that the P7 population
expressed higher levels of a modest number of genes (271
in all at twofold or higher level) on the microarray, and
that an even smaller number of genes were activated in P6
compared to P7 (47 at twofold higher levels). While the
list of genes expressed more strongly in P7 contained
many that have been associated with stem cell phenotype
in previous studies, such as TDGF-1, DPPA4, ZFP42,
DNMT3B, and TERF-1 [11] (see Additional File 1 and
Table 1), many novel molecules potentially critical to the
earliest stages of stem cell differentiation were identified
through this comparison. A number of cell surface mark-
ers not previously associated with hESC were identified,
including six transmembrane epithelial antigen of the
prostate, supervillin, the chondroitin sulphate proteogly-
cans bamacan, versican, and opticin, SIDF, and Intm2a. In
addition, a number of polypeptide regulatory factors and
receptors are also identified, including neurotensin,
adrenomedullin, and the endothelin receptor. It is also of
interest that a number of genes involved in chromatin
remodeling were expressed at highest levels in the P7 pop-
ulation and were downregulated as stem cell surface
marker decreases.
Analysis of genes upregulated as stem cell surface marker
expression decreases pointed to neural differentiation as a
key pathway undergoing activation. Amongst the most
strongly induced genes in the early stages of differentia-
tion are transcription factors characteristic of early neural
lineages such as Pax-6. The early activation of these neu-
ralising factors may account for the tendency of hESC cells
to undergo "spontaneous" neural differentiation under
these conditions of culture [34]. At the same time, the
expression of bone morphogenetic proteins and Wnt
antagonists such as noggin, chordin and dickopf, is acti-
vated. These molecules are known as neuralising factors
from animal embryology [35] and they and other related
molecules are involved in induction of the formation of
the nervous system. Moreover, several surface markers of
these early differentiating populations were identified,
including betaglycan, smoothened, cadherin 6 type 2 and
FGFR3. These cell surface molecules, expressed only at
low levels in P7, may serve to mark the early differentiat-
ing cells from the most primitive stem cell population.
We directly compared our results with the only other
study in the literature to examine gene expression in hESC
sorted by flow cytometry. Enver et al. [36] compared gene
expression in hESC positive for the cell surface glycolipid
antigen SSEA-3 (SSEA-3+) to SSEA-3 negative (SSEA-3-)
cells. Of the 468 genes differentially expressed by their
Affymetrix analysis, 397 could be identified on our Com-
pugen array. 82 genes that were significantly elevated (B
score>0 and >2 fold up regulated) in our P7 population
versus P6, P5, or P4, were also elevated in SSEA-3 positive
cells compared to SSEA-3 negative cells, including TDGF1,
DNMT3B, FLJ12505, GPC4, BMPR1A, ADM, CALB1, KIT,
and TERF1, all identified in previous array studies of
hESC. Further analysis showed that there was greater con-
cordance between the set of genes differentially expressed
in P7 versus P4 and SSEA-3+ cells versus SSEA-3- cells than
between the other sets of comparisons that we carried out.
Thus 75 genes are more highly expressed in both P7 versus
Combined flow cytometric analysis of hESC for GCTM-2,  TG30 and Oct-4 Figure 3
Combined flow cytometric analysis of hESC for GCTM-2, 
TG30 and Oct-4. Gates are set relative to isotype controls. 
A, yellow represents cells with high staining intensity for 
both GCTM-2 and TG30 (R14). B, Percentages of cells stain-
ing for Oct-4 from regions R2, R3, R4 and R14 of figure 3A.BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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FACS of hESC for array analysis Figure 4
FACS of hESC for array analysis. Gates are set relative to isotype controls. A, hESC were separated by FACS according to 
staining intensity for GCTM-2 and TG30 (CD9) into 4 populations; P4 (GCTM-2-CD9-), P5 (GCTM-2LOWCD9LOW), P6 
(GCTM-2MIDCD9MID) and P7 (GCTM-2HIGHCD9HIGH). B, heat map depicting normalized intensity of gene expression for genes 
from P7 V P4 experiment with a B stat greater than zero.BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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Table 1: Microarray analysis of changes in expression level of selected genes across the four cell populations isolated by flow 
cytometry. Bold numerals indicate B-statistic greater than zero, italicized numerals indicate expression levels two-fold or higher in P7 
versus other populations, and grey numerals indicate 0.5 fold or lower expression levels in P7 versus other populations.
Gene
Symbol
Accession 
number
Gene Name fold change
P7 V P4
B 7V4 fold change 
P7 V P5
B 7V5 fold change 
P7 V P6
B 7V6
ACVR2B NM_001106 activin A receptor, type IIB 0.89 -5.4 1.37 -2.7 2.83 2.6
ADM NM_001124 adrenomedullin 8.82 8.2 4.23 4.0 2.55 1.1
AFP NM_001134 alpha-fetoprotein 1.61 1.8 2.06 1.7 1.88 0.4
BNC2 AK001099 Homo sapiens cDNA FLJ10237 
fis, clone HEMBB1000438.
6.54 7.1 6.96 3.8 1.90 4.3
CALB1 NM_004929 calbindin 1, 28 kDa 9.32 3.3 6.36 5.5 2.48 4.6
CCNA2 NM_001237 cyclin A2 2.75 7.9 2.04 1.9 1.46 0.8
CCNE1 M74093 cyclin E1 1.98 7.6 1.43 0.8 1.15 -1.7
CD9 AK025016 Homo sapiens cDNA: FLJ21363 
fis, clone COL02986
1.52 4.9 1.51 0.0 1.35 -3.8
CDH6 NM_004932 cadherin 6, type 2, K-cadherin 
(fetal kidney)
0.36 2.8 0.43 3.9 0.39 3.5
CEBPZ NM_005760 CCAAT-box-binding 
transcription factor
6.15 0.7 2.68 0.6 1.32 -5.6
COL4A6 U04845 collagen, type IV, alpha 6 0.36 5.2 0.44 3.8 0.47 4.0
CRI1 NM_014335 CREBBP/EP300 inhibitory 
protein 1
2.35 2.5 2.39 2.3 2.83 4.4
CRYM NM_001888 crystallin, mu 4.96 9.6 2.68 0.8 1.37 -3.5
CSPG2 NM_004385 chondroitin sulfate proteoglycan 
2 (versican)
2.50 7.0 2.10 -1.1 2.85 2.1
CSPG6 NM_005445 chondroitin sulfate proteoglycan 
6 (bamacan)
3.76 5.0 1.99 3.9 2.81 1.3
CTCF NM_006565 CCCTC-binding factor (zinc 
finger protein)
1.61 -3.2 1.73 1.1 1.15 -3.3
DKFZP586A0522 AF113007 DKFZP586A0522 protein 5.35 5.5 4.76 2.9 3.84 4.6
DKK1 NM_012242 dickkopf homolog 1 (Xenopus 
laevis)
0.33 -0.6 0.36 5.0 0.43 3.6
DNMT3B NM_006892 DNA (cytosine-5-)-
methyltransferase 3 beta
3.14 4.7 2.68 0.9 1.97 1.1
DPPA4 NM_018189 developmental pluripotency 
associated 4
7.52 8.3 5.62 3.0 2.77 2.3
EDN1 NM_001955 endothelin 1 0.45 1.4 0.72 1.2 0.97 -6.7
EDNRB NM_000115 endothelin receptor type B 3.05 6.9 2.27 0.3 1.30 -1.1
FBLN1 NM_006485 fibulin 1 0.37 5.0 0.43 2.9 0.60 1.1
FGFR1 AK001052 Homo sapiens cDNA FLJ10190 
fis, clone HEMBA1004753.
0.67 1.2 0.65 -1.5 0.59 1.8
FGFR3 NM_000142 fibroblast growth factor 
receptor 3 (achondroplasia, 
thanatophoric dwarfism)
0.39 2.3 0.37 3.6 0.42 3.0
FLJ10036 NM_017975 hypothetical protein FLJ10036 
(zwilch)
4.38 3.5 2.57 2.3 2.62 4.0
FLJ12787 AK022849 hypothetical protein FLJ12787 
(Src-associated protein SAW)
3.16 6.3 2.04 1.9 1.34 1.6
FLT1 NM_002019 fms-related tyrosine kinase 1 
(vascular endothelial growth 
factor/vascular permeability 
factor receptor)
4.23 2.0 3.10 3.4 1.67 3.5
FST NM_006350 follistatin 0.22 4.9 0.31 -0.5 0.42 0.9
FZD7 NM_003507 frizzled homolog 7 (Drosophila) 3.76 2.0 1.71 -2.1 1.23 -5.5
GOLGB1 NM_004487 golgi autoantigen, golgin 
subfamily b, macrogolgin (with 
transmembrane signal), 1
2.10 6.2 1.77 1.6 2.83 2.6
GPC4 NM_001448 glypican 4 2.93 6.6 2.68 3.1 1.81 2.1
GREM1 NM_013372 cysteine knot superfamily 1, 
BMP antagonist 1
0.57 -2.5 0.26 6.0 0.49 1.8
HAT1 NM_003642 histone acetyltransferase 1 6.02 3.9 2.35 0.7 1.17 -6.0
HELLS AK021443 Homo sapiens cDNA FLJ11381 
fis, clone HEMBA1000501.
6.87 7.3 6.63 2.1 5.24 1.9BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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HESX1 NM_003865 homeo box (expressed in ES 
cells) 1
2.30 5.5 1.25 -3.0 0.68 -0.8
HSPCA D87666 heat shock 90 kDa protein 1, 
alpha
4.14 0.7 2.71 0.6 2.62 5.4
HSPCB NM_007355 heat shock 90 kDa protein 1, 
beta
3.71 1.6 2.04 3.2 3.63 2.3
KDR AF035121 kinase insert domain receptor (a 
type III receptor tyrosine kinase)
2.53 4.8 1.94 0.1 1.94 1.9
LHX2 NM_004789 LIM homeobox 2 0.04 6.1 0.17 0.5 0.48 1.1
LIFR NM_002310 leukemia inhibitory factor 
receptor
1.91 1.2 1.71 1.8 2.38 1.1
LOC57146 NM_020422 promethin 1.93 4.4 2.35 1.1 4.23 3.2
MSX1 NM_002448 msh homeo box homolog 1 
(Drosophila)
0.16 6.5 0.20 1.3 0.38 0.9
NUP54 NM_017426 nucleoporin 54 kDa 4.17 3.5 1.96 1.3 1.01 -7.3
OPTC NM_014359 opticin 4.79 3.2 4.11 0.4 2.62 0.6
PAX6 NM_001604 paired box gene 6 (aniridia, 
keratitis)
0.04 3.5 0.13 0.9 0.29 2.5
PB1 NM_018165 polybromo 1 1.45 1.8 1.54 -0.4 2.23 1.7
PODXL NM_005397 podocalyxin-like 7.31 4.9 2.22 0.6 1.38 -3.8
SAS10 NM_020368 disrupter of silencing 10 3.20 6.4 3.58 2.6 3.20 3.4
SCAMP3 NM_005698 secretory carrier membrane 
protein 3
0.48 2.9 0.51 1.4 0.57 2.0
SDFR1 NM_012428 stromal cell derived factor 
receptor 1
3.66 6.1 2.50 0.0 1.51 -0.8
SFRP1 NM_003012 secreted frizzled-related protein 
1
3.97 3.3 2.99 1.7 1.85 -1.4
SLIT1 NM_003061 slit homolog 1 (Drosophila) 0.29 2.6 0.40 1.5 0.69 0.8
SMARCA2 NM_003070 SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 
subfamily a, member 2
4.72 6.8 3.58 -0.3 2.50 1.1
SMO NM_005631 smoothened homolog 
(Drosophila)
0.32 5.4 0.33 2.5 0.43 2.4
SOX1 NM_005986 SRY (sex determining region Y)-
box 1
2.69 0.9 1.34 -2.7 1.70 0.6
STEAP2 AK026813 six transmembrane epithelial 
antigen of prostate 2
4.72 9.4 2.73 1.2 2.85 3.5
T NM_003181 T, brachyury homolog (mouse) 1.04 -7.3 0.98 -7.3 1.01 -7.4
TERF1 NM_017489 telomeric repeat binding factor 
(NIMA-interacting) 1
11.31 4.0 6.50 4.8 2.04 3.1
TGFBR3 NM_003243 transforming growth factor, beta 
receptor III (betaglycan, 300 
kDa)
0.37 8.5 0.39 2.6 0.52 1.8
VEGFC NM_005429 vascular endothelial growth 
factor C
0.46 0.7 0.68 1.5 0.85 -3.7
ZFP42 NM_003422 zinc finger protein 42 (myeloid-
specific retinoic acid-responsive)
0.37 5.1 0.56 2.3 0.80 -2.4
Table 1: Microarray analysis of changes in expression level of selected genes across the four cell populations isolated by flow 
cytometry. Bold numerals indicate B-statistic greater than zero, italicized numerals indicate expression levels two-fold or higher in P7 
versus other populations, and grey numerals indicate 0.5 fold or lower expression levels in P7 versus other populations. (Continued)
P4 as well as SSEA-3+ versus SSEA-3- cells (~19% of P7 ver-
sus P4 gene list), while 36 genes are more highly expressed
in both P7 versus P5 and SSEA-3+ versus SSEA-3- cells
(~7% of P7 V P5 genelist), and only 28 genes are more
highly expressed in both P7 versus P6 and SSEA-3+ versus
SSEA-3- cells (approx 9% of P7 V P6 gene list). In sum-
mary, our study, which compared hESC populations
expressing different levels of stem cell antigens, identified
a different set of regulated genes to this previous study,
which compared cells expressing stem cell antigens to
cells that did not. As expected, the greatest overlap
between the two studies was seen in our comparison of
cells expressing the highest level of stem cell antigens to
the negative cells.BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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QRT-PCR confirms coordinated downregulation of 
pluripotency genes and concomitant activation of 
transcription factors associated with induction of 
extraembryonic endoderm and neurectoderm
The results described above were confirmed and extended
by QRT-PCR using ABI Microfluidic card analysis of 96
genes selected in part from those identified in the array
analysis, and some key stem cell maintenance factors and
differentiation markers that were not represented on the
array or failed to read out. Two separate hESC lines were
immunologically fractionated as described above, RNA
was prepared, cDNA was synthesised, and analysed for
expression of the genes shown. Downregulation of tran-
script levels of a number of known and novel markers of
the pluripotent state was confirmed (Figures 5 &6). Tran-
scripts for CD9, which was used for flow cytometry sorting
of the population, showed the expected reduction, as did
many other markers of the pluripotent state. The QRT-
PCR analysis highlighted that genes that are activated
early on after loss of stem cell markers include genes
expressed in extraembryonic endoderm and neural genes
(Figures 7 &8). Thus, the transcription factors GATA-4,
GATA-6, and FOXA1 are all activated, as is the Wnt antag-
onist dickopf; these transcription factors are critical to the
differentiation of primitive endoderm in the mammalian
embryo, and dickopf is secreted by this tissue. Note that in
Figures 5, 6, 7, 8, the use of a value of 100 on the y-axes to
indicate expression levels relative to the P7 or P4 popula-
tion (depending on which was higher), and based on
either array or QRT-PCR, enables comparison of the data
but also compresses its display, and can thus obscure sig-
nificant differences where the overall change in expression
is large. For example, the relative fold change in Pax-6
expression for HES-2 in the array data was 3.5 (P6), 7.4
(P5) and 27 (P4) relative to P7, and the corresponding
data for QRT-PCR 5.0, 88, and 135 fold. Thus there is
clearly activation of Pax-6 expression in P6 versus P7 by
either technique, but the graphic display of this in Figure
7 is influenced by the massive overall change between P7
and P4.
The analysis also confirmed the induction of BMP and
TGF-beta antagonists including chordin, noggin, gremlin,
and follistatin. These genes are transcribed in tissues
involved in patterning in the mouse postimplantation
embryo, the node and the anterior mesendoderm, and
they function to drive commitment of pluripotent cell
populations to neural fates. Possibly as a consequence of
the production of these anteriorising factors, transcription
factors characteristic of neurectoderm are activated during
differentiation prior to overt loss of stem cell marker
expression (Figure 7B), and the transcription factors char-
acteristic of mesendodermal lineages (T, MixL-1 and goo-
secoid) are switched off. The picture is consistent with the
early commitment of ES cells to the extraembyonic line-
age and the subsequent elaboration of factors from these
cells and other cell types that drive neural commitment. It
is important to note that the expression of most of these
lineage specific transcription factors begins to rise well
before extinction of expression of markers of pluripo-
tency.
Expression of certain surface markers for ES and differen-
tiated cells was also confirmed (Figures 5A &8A), as was
the downregulation of a number of genes involved in
chromatin structure (Figure 6A).
Discussion
The hESC phenotype has been defined at the immunolog-
ical, transcriptional, and biological levels. This study has
shown that flow cytometric sorting based on quantitative
levels of expression of two surface markers, the GCTM-2
antigen and CD9, allows fractionation of the hESC popu-
lation into subsets expressing varying levels of pluripo-
tency genes. The GCTM-2 antigen is not exclusive to
primate pluripotent stem cells, but its expression is
informative of stem cell status in a restricted context. The
function of this proteoglycan is unknown. It is of interest
that our array studies found that several known chondroi-
tin sulphate proteoglycan core proteins were highly
expressed in stem cells and rapidly downregulated during
the early stages of differentiation. It is now appreciated
that, like the better-studied heparan sulphate proteogly-
cans, chondroitin sulphate proteoglcyans can function to
present growth factors to cells [37]. Thus these chondroi-
tin sulphate proteoglycans may represent an important
component of the hESC microenvironment. CD9 is a tet-
raspannin protein thought to function in organizing
integrins and other receptors at the cell surface. There is
some evidence to implicate the molecule in ES cell main-
tenance in the mouse [38]. CD9 transcript levels, meas-
ured by microarray or Q-RTPCR, correlated well with
levels of the protein as determined by flow cytometry.
For this study, we cultured hESC in the presence of a fibro-
blast feeder cell layer and fetal calf serum, using mechan-
ical dissociation to passage the cells. This method
provides for long term support of diploid populations of
hESC. Other culture methodologies may give rise to the
appearance of chromosome abnormalites in hESC cul-
tures [39-41]. Since these abnormal cells often have
altered growth and differentiation properties [36,41],
which reflect changes at the level of gene transcription,
and since it is not clear at what stage during their emer-
gence the phenotypic changes occur, we conducted our
study using a culture method that reliably maintains the
diploid state. It will be of interest to carry out this analysis
on cells grown under different conditions. Preliminary
data indicate that there is a similar continuum of markerBMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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Relative gene expression levels of combined array and QRT-PCR analyses of P4, P5, P6 and P7 Figure 5
Relative gene expression levels of combined array and QRT-PCR analyses of P4, P5, P6 and P7. Stem cell markers are pre-
sented relative to P7 (set at 100). A, stem cell markers: cell surface or secreted factors. B, stem cell markers: transcription fac-
tors.BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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expression in cultures grown in FGF-2 and proprietary
serum replacement.
The use of several surface markers enabled separation of
the hESC population into subsets of cells at various stages
of differentiation, as indicated by their expression of stem
cell markers and lineage specific transcription factors. Per-
haps because the cell populations we examined are so
closely related, relatively few genes showed significant
changes in transcript levels across the cell populations
studied, and some novel candidate surface markers and
stem cell regulators were identified. Novel surface markers
will facilitate identification of stem cell subpopulations
and early differentiated cells. Ligands such as endothelin
and their cognate receptors may have roles in stem cell
regulation.
Relative gene expression levels of combined array and qPCR analyses of P4, P5, P6 and P7 Figure 6
Relative gene expression levels of combined array and qPCR analyses of P4, P5, P6 and P7. Stem cell markers are presented 
relative to P7 (set at 100). A, stem cell markers: genes involved in chromatin structure. B, stem cell markers: miscellaneous 
genes.BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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Relative gene expression levels of combined array and QRT-PCR analyses of P4, P5, P6 and P7 Figure 7
Relative gene expression levels of combined array and QRT-PCR analyses of P4, P5, P6 and P7. Differentiation markers are 
presented relative to P4 (set at 100). A, differentiation markers: extraembryonic. B, differentiation markers: neural.BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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In addition to these surface molecules and receptors and
ligands, it is notable that a number of genes with known
or suspected function in chromatin remodeling were
downregulated during the early phases of stem cell differ-
entiation. Although chromatin remodeling is clearly
important during differentiation, and chromatin remode-
ling proteins are thought to be critical components of
oocyte cytoplasm for the reprogramming process that
occurs in the donor nucleus during cloning by somatic
cell nuclear transfer, previous studies have not reported an
overall downregulation of these molecules during stem
cell differentiation. The study of Boyer et al. [27] identi-
fied chromatin remodeling complexes as targets of Oct-4.
It is possible that chromatin plasticity is an essential fea-
ture of the pluripotent state and that expression of remod-
eling factors is therefore important to stem cell
maintenance. In Arabadopsis, maintenance of the
pluripotent stem cell population of the apical meristem
depends on expression of both specific transcription fac-
tors and a set of chromatin remodeling factors [42]. Defi-
ciencies in chromatin remodeling factors (ISWI) lead to
loss of germline stem cells in Drosophila, due to defects in
the response of the cells to signals from the niche and a
loss of suppression of differentiation [43]. Recently results
based on quantitative in vivo imaging and biochemical
examination of chromatin proteins in mouse ES cells
strongly argues that a highly dynamic state of architectural
chromatin proteins is associated with pluripotency [44].
It is clear from these results that stem cell maintenance
factors are co-expressed at early stages of the differentia-
tion process along with a number of transcription factors
Relative gene expression levels of combined array and QRT-PCR analyses of P4, P5, P6 and P7 Figure 8
Relative gene expression levels of combined array and QRT-PCR analyses of P4, P5, P6 and P7. Differentiation markers are 
presented relative to P4 (set at 100). A, differentiation markers: miscellaneous cell surface or secreted factors. B, differentia-
tion markers: miscellaneous transcription factors.BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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characteristic of commitment to extraembryonic endo-
derm, mesendoderm, and neural lineages. As expression
of hESC markers decline, markers of neural and extraem-
bryonic lineages remain on or increase, whereas meso-
derm marker expression decline. The coexpression of stem
cell and lineage specific transcription factors was first
described in stem cells of the hematopoietic lineage
[24,25], where the phenomenon has come to be known as
lineage priming. In essence the concept states that stem
cells, rather than completely repressing lineage specific
commitment genes, express these genes at low levels
pending internal or external signals that activate specific
differentiation programs fully. In our case, neuralising sig-
nals, in part from extraembryonic endoderm, may func-
tion to drive this outcome. Although the lineage priming
model has been questioned, on the grounds that the cells
expressing lineage specific markers might represent cells
already committed to differentiation, marking of hemat-
opoietic stem cells using cre recombinase driven by the
myeloid lineage specific promoter for lysozyme, showed
that marked cells which activated the gene were capable of
long term renewal and multipotent differentiation [45].
Ultimately, it will be critical to define the developmental
potential of these various subpopulations of hESC. Cur-
rently, technical limitations restrict our ability to examine
this question in detail. Isolation and clonal analysis of sin-
gle hESC following flow cytometry sorting is problematic
at present, due to low cell survival, but our preliminary
results indicate that the cells with reduced surface marker
expression, shown here to display activation of specific
lineage commitment programs at the transcriptional level,
are clearly capable of maintaining a stem cell phenotype.
It should be noted that although we used two independ-
ent markers to fractionate the cell population, the frac-
tions we obtained are still likely to be heterogeneous.
Andrews and colleagues [36] analysed hESC cultures and
separated them into populations which were positive or
negative for the surface marker SSEA-3; they concluded
that SSEA-3 negative cells were an intermediate popula-
tion between the pluripotent state and fully committed
cells. Whether the cells with the highest levels of surface
marker and pluripotency gene expression are already
primed at the transcriptional level will require more
refined analysis of the population, but some lineage spe-
cific factors are expressed at appreciable levels even in this
population.
These results have implications for interpretation of bio-
chemical and molecular studies on hESC, and for practical
approaches to their propagation and manipulation.
Clearly interpretation of molecular studies of hESC
should take the heterogeneity of the cultured cell popula-
tion into account. The presence of hESC subpopulations
that are apparently primed for commitment to different
cell fates, at least at the transcriptional level, suggests that
the large scale production of pure populations of pluripo-
tent cells or committed progenitors will require a much
better understanding of the dynamics of these early stages
of commitment and the interactions of the various cellu-
lar subpopulations that are present in the culture. Moreo-
ver, these results point to a special role for ES cells in
fundamental research aimed at understanding the cellular
and molecular basis of fate determination. Because they
may be grown in large numbers and readily fractionated
by immunological means into populations at very early
and defined stages of determination, hESC may represent
an excellent model system for studying how lineage com-
mitment occurs in a stem cell population and for defining
the molecular events that accompany loss of pluripotency.
Conclusion
Human embryonic stem cell cultures contain a heteroge-
neous mixture of cells representing a continuum along a
differentiation hierarchy. Cells in this hierarchy co-
express stem cell markers along with transcription factors
characteristic of specific differentiation lineages.
Methods
Cell Culture
hESC lines HES-2, -3, and -4 were grown as previously
described [5], using serum containing medium, mouse
embryonic fibroblast feeder cell support, and mechanical
dissection of colonies for subculture. This methodology
was used for hESC culture because in our hands this
approach provides for long-term maintenance of pluripo-
tent stem cells with a normal diploid karyotype.
Indirect immunofluorescence
Triple indirect immunofluorescent staining for GCTM-2,
Oct-4 and TG30 was carried out using isotype specific sec-
ondary antibodies. Oct-4 was detected with anti-mouse
IgG2bAF568 (1:1000), TG30 with anti-mouse
IgG2aAF488 (1:1000) and GCTM-2 with biotinylated
anti-mouse IgM (1:125, Dako) followed by streptavidin
AF350 (1:1000, all from Molecular Probes). Double or tri-
ple stained slides were counterstained with DAPI and
mounted in ProLong Antifade (Molecular Probes, OR,
USA).
Immunohistochemistry
Normal human kidney tissue was obtained from the
uninvolved pole of renal carcinoma nephrectomy speci-
mens (approved by the Monash Medical Centre Human
Research Ethics Committee). Sections (4 μm) of formalin-
fixed, paraffin embedded tissue were dewaxed, hydrated
in PBS and blocked in 10% normal sheep serum and 10%
foetal calf serum in PBS for 30 min. Sections were incu-
bated overnight with GCTM-2 or PHM-5 [46] antibody at
4°C, washed (x3) in PBS; endogenous peroxidase wasBMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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inactivated in 0.6% H2O2 in methanol for 20 min, and the
sections washed in PBS. Sections were then incubated
with either horseradish peroxidase (HRP)-conjugated
goat anti-mouse IgG (Dako, Glostrup, Denmark) (for
detection of PHM-5) or goat anti-mouse IgM (Serotec,
Oxford, UK) (for detection of GCTM-2) in 5% normal
sheep serum and 3% bovine serum albumin in PBS for 40
min, washed (x3) in PBS, incubated with complexes of
HRP-conjugated mouse anti-HRP IgG complexes (Dako),
washed (x3) in PBS and developed with the diaminoben-
zidine substrate (Sigma-Aldrich, Castle Hill, NSW, Aus-
tralia) to produce a brown colour.
Mammalian expression of recombinant podocalyxin and 
immunoblot analysis
Preliminary attempts to express recombinant human
podocalyxin in mouse STO cells resulted in the produc-
tion of a protein immunoreactive with monoclonal anti-
bodies specific for human podocalyxin, but this protein
was much smaller than the canonical form, suggesting
either premature termination of transcription or transla-
tion, partial degradation, or incomplete glycosylation. We
reasoned that a mouse cell line that normally expresses
the protein might produce mature full-length human
podocalyxin when transfected with recombinant cDNA.
Mouse M15 cells, derived from embryonic mesonephros
[47], were grown in Dulbecco's Modified Eagle's Medium
(high glucose formulation) supplemented with 20% foe-
tal calf serum, penicillin and streptomycin and L-
glutamine. For transfection, M15 cells were plated on T-75
flasks the day before to allow 50–80% confluency at the
time of transfection. An hour before transfection, media
was replaced with serum-free, supplemented media. For
each transfection, 30 μL Fugene 6 was diluted in 470 μL of
serum-free media. DNA at a ratio of (v/w) 3:1 (Fugene 6:
DNA) was then added and incubated for 15 mins at room
temperature. The mixture was added dropwise to the cells
which were incubated at 37°C with 5% CO2. 5 hours after
transfection, the media was replaced with serum-contain-
ing, supplemented media. Cells were lysed 48 hours post-
transfection using lysis buffer containing 10 mM Tris-HCl
buffer (pH 7.0), 1% Triton X-100 detergent and 1 mM
EDTA in water. 1 mM phenylmethanesulfonyl flouride
diluted in isopropanol was added to the lysis buffer prior
to use. Protein lysate samples were separated in a 6%
reducing SDS-PAGE gel and transferred for 1 hour at 75
mAmps onto a PVDF membrane. Blots were blocked in
5% skim milk powder in PBS-Tween overnight and incu-
bated with the monoclonal antibodies GCTM2, podoca-
lyxin (PHM-5) and TG343 for 1 hour. Washed blots were
then incubated with the secondary antibody anti-mouse
Ig-HRP for an hour and the blots were developed with
ECL.
FACS Analysis and Cell Sorting
For analysis of co-expression of Oct-4 and surface mark-
ers, harvested hESC were dissociated into single cell sus-
pension by trituration and fixed with 100% methanol.
Cells were then stained with a mixture of mouse IgM
GCTM-2, mouse TG30 (anti-CD9) IgG2a and mouse Oct-
4 IgG2b or a mixture of class matched negative control
antibodies. Binding of primary antibodies was detected by
incubation with biotinylated rabbit anti-mouse IgM, fol-
lowed by a mixture of goat anti-mouse IgG2a-AF488, goat
anti-mouse IgG2b AF647 and streptavidin-PE. Samples
were assayed on a flow cytometer (FACS Vantage-SE Diva,
Becton Dickinson). Cells were gated initially using for-
ward and right angle light scatter and AF488, AF647 and
PE fluorescence signals were collected. hESC cells ana-
lysed via the above method were compared to single color
controls for TG30, GCTM-2 and Oct-4 and parallel analy-
ses examined live, non-fixed, human ES cells for the pres-
ence of the cell surface markers GCTM-2 and TG30. Co-
incubation of the primary antibodies with each other and
with fixed or non-fixed human ES cells did not affect the
percentages of cells displaying immunofluorescence for
each antibody.
For preparative isolation of discrete cell populations for
RNA analysis, unfixed hESC were harvested and stained in
solution for GCTM-2, TG30 (CD9) and Thy1.2-PE (to gate
out any remaining mouse embryo fibroblasts) as above,
except that the secondary antibodies used were goat anti-
mouse IgG2a-AF488 (Molecular Probes, Oregon, USA)
and goat anti-mouse IgM AF647 (Molecular probes, Ore-
gon, USA). Cells were sorted four ways into microfuge
tubes (P4, P5, P6 and P7, see Figure 4a above) using the
FACSVantage-DIVA (BDBiosciences). Sorted cells were
initially gated using forward and side scatter, followed by
the removal of clumps and doublets by gating on single
cells (FSC-A vs. FSC-H), and the removal of MEF feeder
cells using negative selection for Thy1.2-PE.
Microarray analysis
RNA amplification and target labelling
Total RNA from the sorted fractions described above was
isolated using Trizol and linearly amplified using the mes-
sageAMP aRNA kit (Ambion) yielding a minimum of 10
micrograms of amino-allyl labeled anti-sense aRNA. The
quantity and integrity of these aRNAs was compared via
running each sample on a bio-analyser RNA micro-fluidic
chip (Agilent) prior to labelling. 5 micrograms of each
aRNA sample was then labelled by covalent linking Cy5-
or Cy3-labelled UTP (Amersham). Finally the labelled
material was hydrolysed and used for hybridisation.
Array fabrication and generation
The arrays used were obtained from the SRC Microarray
Facility, University of Queensland (ARC Centre for Func-BMC Developmental Biology 2007, 7:12 http://www.biomedcentral.com/1471-213X/7/12
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tional and Applied Genomics) and comprised 17260
human gene-specific oligonucleotides (Compugen) spot-
ted onto epoxy-silane coated slides (Fullmoon). Arrays
were hybridised for a minimum of 16 hours at 45°C using
previously described conditions [48].
Image Analysis, normalisation and analysis
Hybridised slides were washed, dried and scanned in a
600B array scanner (Agilent). The images were analysed
with Imagene 5.5 (BioDiscovery Inc) to determine mean
foreground and background for both channels. All pri-
mary data, including images was then imported into an
in-house installation of the comprehensive microarray
relational database, BASE [49].
The raw data from each hybridisation was compiled into
an experiment and subjected to print tip intensity inde-
pendent Lowess normalisation using the R statistical soft-
ware from the LIMMA package [50]. This normalisation is
implemented within BASE using scripts developed by Ola
Spjuth of the Linnaeus Centre for Bioinformatics [51].
Gene lists, along with MA-plots and box plots showing the
normality of the data are available via the BASE database
cited above (login Laslett 2006, Password: HES).
Experimental design
The four FACS sorted populations were compared to one
another in a boxed experimental design where each sam-
ple is compared to the other in at least triplicate; a dye-
swap was included to account for dye bias. Differential
expression was defined using a robust statistical method
rather than simple fold change. All genes were ranked
using the B statistic method where both fold change and
variance of signals in replicates is used to determine the
likelihood that genes are truly differentially expressed. A
threshold in the B statistic of 0.0 was adopted as genes
with a B score>0 have a >50% probability of being truly
expressed [52]. This analysis was executed using the Bio-
conductor package that has been implemented as a plug
in tool in BASE, where the actual B values may be found.
Data deposition note: The full array dataset is available
from Gene Expression Omnibus (GEO, Accession
Number GSE4020) [53].
Q-RT-PCR confirmation of gene expression patterns
We used the ABI Microfluidic Card system for quantitative
RT-PCR validation of patterns of gene expression. We
designed a 384 well format card enabling assay of 96 tar-
get genes on four samples. The card incorporates proprie-
tary validated RT-PCR primers for key genes identified in
our original studies as strongly up- or down-regulated
during early phases of hESC differentiation, plus a
number of classical hESC genes and a number of genes
characteristic of early differentiation pathways. To carry
out analyses, total RNA (1 μg) was isolated, reverse tran-
scribed, and 100 ng introduced into the gene card in PCR
mastermix. Amplification was carried out in the ABI Prism
7900 HT system at the Australian Genome Research Facil-
ity Melbourne Node, and analysed using the comparative
CT method using the proprietary sequence detection soft-
ware.
The comparison of expression levels was carried out with
reference calibration to the population of cells with the
highest level of stem cell marker expression.
Abbreviations
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hESC – human embryonic stem cells
QRT-PCR – quantitative reverse transcriptase polymerase
chain reaction
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